Addition of Low-Dose Decitabine to Anti–PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma In a prospective, multicenter, randomized phase III trial, patients with cN0 early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results